Shire (SHP) Downgraded to “Hold” at Liberum Capital
Liberum Capital cut shares of Shire (LON:SHP) to a hold rating in a report issued on Wednesday. The brokerage currently has GBX 4,100 ($55.18) price target on the biopharmaceutical company’s stock, down from their previous price target of GBX 4,200 ($56.53).
A number of other analysts also recently weighed in on the stock. Deutsche Bank reaffirmed a buy rating on shares of Shire in a report on Monday, December 11th. Citigroup reaffirmed a buy rating and set a GBX 5,500 ($74.02) price target on shares of Shire in a report on Friday, December 8th. Morgan Stanley reaffirmed an overweight rating and set a GBX 5,700 ($76.72) price target on shares of Shire in a report on Friday, December 1st. Societe Generale upped their price target on shares of Shire from GBX 7,500 ($100.94) to GBX 8,000 ($107.67) and gave the stock a buy rating in a report on Wednesday, November 29th. Finally, Goldman Sachs Group reaffirmed a conviction-buy rating and set a GBX 6,000 ($80.75) price target on shares of Shire in a report on Friday, November 24th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of GBX 5,272.22 ($70.96).
Shares of Shire (LON SHP) traded up GBX 52.50 ($0.71) during trading on Wednesday, hitting GBX 3,916 ($52.71). 2,846,007 shares of the stock were exchanged, compared to its average volume of 2,510,000. Shire has a 12 month low of GBX 3,435.50 ($46.24) and a 12 month high of GBX 5,067 ($68.20).
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.